Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platycodin D is a **triterpene saponin** isolated primarily from the root of *Platycodon grandiflorum* (commonly known as balloon flower). It is a bioactive natural compound with demonstrated multiple pharmacological effects, including anticancer, anti-inflammatory, antiviral, and immunoregulatory properties. Platycodin D exhibits **anticancer** effects in various cell lines by *inducing apoptosis, cell cycle arrest, and autophagy* and by inhibiting angiogenesis, invasion, and metastasis[1][3][4][7]. Mechanistically, it modulates several cell signaling pathways relevant to cancer biology, such as upregulating the Bax/Bcl-2 ratio, activating caspase-3, promoting ubiquitin-proteasome-dependent c-Myc degradation, and downregulating the PI3K/AKT/mTOR signaling pathway as well as redistributing membrane cholesterol and interfering with viral entry in the case of SARS-CoV-2[1][3][4][6]. Platycodin D is used primarily in preclinical research and is not currently an approved pharmaceutical drug for any indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platycodin d.